
Surgical Science Q2 2024 - Solid sequential recovery, decent outlook

Redeye updates its estimates following Surgical Science's Q2 2024 report, which featured a sequential recovery after the company's weak Q1. Potential large orders in Educational Products might fuel sales growth in H2 2024e and 2025e. Further, Intuitive's broader da Vinci 5 rollout should boost Industry/OEM growth in 2025e. We finetune our estimates and valuation.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Surgical Science Q2 2024 - Solid sequential recovery, decent outlook](#)